Literature DB >> 29902132

Roles of the bone marrow niche in hematopoiesis, leukemogenesis, and chemotherapy resistance in acute myeloid leukemia.

Andi Wang1, Hua Zhong1.   

Abstract

OBJECTIVES: To summarize the effects of the bone marrow niche on hematopoiesis and leukemogenesis and discuss the chemotherapy resistance that can arise from interactions between the niche and leukemia stem cells.
METHODS: We review the major roles of the bone marrow niche in cell proliferation, adhesion and drug resistance. The signaling pathways and major molecular participants in the niche are discussed. We also address potential niche-targeting strategies for the treatment of acute myeloid leukemia (AML).
RESULTS: The bone marrow niche supports normal hematopoiesis and affects acute myeloid leukemia (AML) initiation, progression and chemotherapy resistance. DISCUSSION: AML is a group of heterogeneous malignant diseases characterized by the excessive proliferation of hematopoietic stem and/or progenitor cells. Even with intensive chemotherapy regimens and stem cell transplantation, the overall survival rate for AML is poor. The bone marrow niches of malignant cells are remodeled into a leukemia-permissive environment, and these reformed niches protect AML cells from chemotherapy-induced cell death. Inhibiting the cellular and molecular interactions between the niche and leukemia cells is a promising direction for targeted therapies for AML treatment.
CONCLUSIONS: Interactions between leukemia cells and the bone marrow niche influence hematopoiesis, leukemogenesis, and chemotherapy resistance in AML and require ongoing study. Understanding the mechanisms that underlie these interactions will help identify rational niche-targeting therapies to improve treatment outcomes in AML patients.

Entities:  

Keywords:  Bone marrow niche; acute myeloid leukemia; chemotherapy resistance; leukemogenesis

Mesh:

Year:  2018        PMID: 29902132     DOI: 10.1080/10245332.2018.1486064

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  29 in total

1.  Modelling acute myeloid leukemia (AML): What's new? A transition from the classical to the modern.

Authors:  Annachiara Dozzo; Aoife Galvin; Jae-Won Shin; Santo Scalia; Caitriona M O'Driscoll; Katie B Ryan
Journal:  Drug Deliv Transl Res       Date:  2022-08-05       Impact factor: 5.671

Review 2.  Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Authors:  Georgios Petros Barakos; Eleftheria Hatzimichael
Journal:  Diseases       Date:  2022-06-10

3.  METTL3 mediates chemoresistance by enhancing AML homing and engraftment via ITGA4.

Authors:  Mingying Li; Jingjing Ye; Yuan Xia; Meng Li; Guosheng Li; Xiang Hu; Xiuhua Su; Dongmei Wang; Xin Zhao; Fei Lu; Jingxin Li; Daoxin Ma; Tao Sun; Chunyan Ji
Journal:  Leukemia       Date:  2022-10-20       Impact factor: 12.883

4.  Cell interactions in the bone marrow microenvironment affecting myeloid malignancies.

Authors:  Konstantinos D Kokkaliaris; David T Scadden
Journal:  Blood Adv       Date:  2020-08-11

Review 5.  The role of exosomes and MYC in therapy resistance of acute myeloid leukemia: Challenges and opportunities.

Authors:  Nithya Mudgapalli; Palanisamy Nallasamy; Haritha Chava; Srinivas Chava; Anup S Pathania; Venugopal Gunda; Santhi Gorantla; Manoj K Pandey; Subash C Gupta; Kishore B Challagundla
Journal:  Mol Aspects Med       Date:  2019-10-14

Review 6.  Adhesion Deregulation in Acute Myeloid Leukaemia.

Authors:  Alicja M Gruszka; Debora Valli; Cecilia Restelli; Myriam Alcalay
Journal:  Cells       Date:  2019-01-17       Impact factor: 6.600

7.  Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment.

Authors:  Alessandra Trojani; Ester Pungolino; Alessandra Dal Molin; Milena Lodola; Giuseppe Rossi; Mariella D'Adda; Alessandra Perego; Chiara Elena; Mauro Turrini; Lorenza Borin; Cristina Bucelli; Simona Malato; Maria Cristina Carraro; Francesco Spina; Maria Luisa Latargia; Salvatore Artale; Pierangelo Spedini; Michela Anghilieri; Barbara Di Camillo; Giacomo Baruzzo; Gabriella De Canal; Alessandra Iurlo; Enrica Morra; Roberto Cairoli
Journal:  PLoS One       Date:  2019-07-18       Impact factor: 3.240

Review 8.  Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.

Authors:  Daniel Arthur Corpuz Fisher; Jared Scott Fowles; Amy Zhou; Stephen Tracy Oh
Journal:  Front Immunol       Date:  2021-06-01       Impact factor: 8.786

Review 9.  Therapeutic Targeting of the Leukaemia Microenvironment.

Authors:  Vincent Kuek; Anastasia M Hughes; Rishi S Kotecha; Laurence C Cheung
Journal:  Int J Mol Sci       Date:  2021-06-26       Impact factor: 5.923

10.  The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance.

Authors:  Sunil K Joshi; Tamilla Nechiporuk; Daniel Bottomly; Paul D Piehowski; Julie A Reisz; Janét Pittsenbarger; Andy Kaempf; Sara J C Gosline; Yi-Ting Wang; Joshua R Hansen; Marina A Gritsenko; Chelsea Hutchinson; Karl K Weitz; Jamie Moon; Francesca Cendali; Thomas L Fillmore; Chia-Feng Tsai; Athena A Schepmoes; Tujin Shi; Osama A Arshad; Jason E McDermott; Ozgun Babur; Kevin Watanabe-Smith; Emek Demir; Angelo D'Alessandro; Tao Liu; Cristina E Tognon; Jeffrey W Tyner; Shannon K McWeeney; Karin D Rodland; Brian J Druker; Elie Traer
Journal:  Cancer Cell       Date:  2021-06-24       Impact factor: 38.585

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.